Species distribution and susceptibility of Candida isolates from patient with vulvovaginal candidiasis in Southern China from 2003 to 2012

Journal de Mycologie Medicale

Volumn 24, Issue 2, 2014, Pages 106-111

  Liu, X P ^a   Fan, S R ^a   Peng, Y T ^a   Zhang, H P ^a  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

Author keywords

Candida species; Susceptibility; Vulvovaginal candidiasis

Indexed keywords

CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; MICONAZOLE; NYSTATIN; ANTIFUNGAL AGENT;

ADULT; AGAR DIFFUSION; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA HUMICOLA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHINA; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; FEMALE; FUNGAL STRAIN; FUNGUS CULTURE; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; RHODOTORULA; SACCHAROMYCES CEREVISIAE; SPECIES DISTRIBUTION; VAGINA CANDIDIASIS; ANTIFUNGAL RESISTANCE; CANDIDIASIS, VULVOVAGINAL; CLASSIFICATION; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; YOUNG ADULT;

CANDIDA; DEBARYOMYCES HANSENII; SACCHAROMYCES CEREVISIAE;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; CHINA; DRUG RESISTANCE, FUNGAL; FEMALE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOLOGICAL TYPING TECHNIQUES; YOUNG ADULT;

EID: 84902543128     PISSN: 11565233     EISSN: 17730449     Source Type: Journal    
DOI: 10.1016/j.mycmed.2014.01.060     Document Type: Article

References (18)

1. Achkar J.M., Fries B.C. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010, 23:253-273.
2. Ahmad A., Khan A.U. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol 2009, 144:68-71.
3. Amouri I., Sellami H., Borji N., Abbes S., Sellami A., Cheikhrouhou F., et al. Epidemiological survey of vulvovaginal candidosis in Sfax, Tunisia. Mycoses 2011, 54:e499-e505.
4. Asticcioli S., Sacco L., Daturi R., Matti C., Nucleo E., Zara F., et al. Trends in frequency and in vitro antifungal susceptibility patterns of Candida isolates from women attending the STD outpatients clinic of a tertiary care hospital in Northern Italy during the years 2002-2007. New Microbiol 2009, 32:199-204.
5. Barnhart K. Safety and efficacy of bedtime versus day time administration of the miconazole nitrate 1200mg vaginal ovule insert to treat vulvovaginal candidiasis. Curr Med Res Opin 2005, 21:127.
6. Consolaro M.E.L., Albertoni T.A., Svidzinski A.E., Peralta R.M., Svidzinski T.I.E. Vulvovaginal candidiasis is associated with the production of germ tubes by Candida albicans. Mycopathologia 2005, 159:501-507.
7. Fan S.R., Liu X.P. Non-albicans Candida species and antifungal susceptibility. Int J Gynecol Obstet 2007, 98:158-159.
8. Fan S.R., Liu X.P. In vitro miconazole susceptibility and clinical outcome in vulvovaginal candidiasis. Int J Gynaecol Obstet 2007, 97:207-208.
9. Fan S.R., Liu X.P., Li J.W. Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006. J Obstet Gynaecol Res 2008, 34:561-566.
10. Gross N.T., Arias M.L., Moraga M., Baddasarow Y., Jarstrand C. Species distribution and susceptibility to azoles of vaginal yeasts isolated prostitutes. Infect Dis Obstet Gynecol 2007, 2007:82412.
11. Holland J., Young M.L., Lee O., Chen C.-A.S. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect 2003, 79:249-250.
12. Mahmoudi Rad M., Zafarghandi S., Abbasabadi B., Tavallaee M. The epidemiology of Candida species associated with vulvovaginal candidiasis in an Iranian patient population. Eur J Obstet Gynecol Reprod Biol 2011, 155:199-203.
13. Richter S.S., Galask R.P., Messer S.A., Hollis R.J., Diekema D.J., Pfaller M.A. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005, 43:2155-2162.
14. Singh S., Sobel J.D., Bhargava P., Boikov D., Vazquez J.A. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002, 35:1066-1070.
15. Sobel J.D. Vulvovaginal candidosis. Lancet 2007, 369:1961-1971.
16. Sobel J.D., Zervos M., Reed B.D., Hooton T., Soper D., Nyirjesy P., et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob Agents Chemother 2003, 47:34-38.
17. Sobel J.D., Chaim W., Nagappan V., Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003, 189:1297-1300.
18. Workowski K.A., Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010, 59:1-110. Centers for Disease Control and Prevention [CDC], [RR-12].